Compositions and methods for treating and preventing neointimal stenosis

COMPOSITIONS AND METHOD FOR TREATING AND PREVENTING NEOINTIMAL STENOSIS CROSS REFERENCE TO RELATED APPLICATIONS

This application claims benefit of U.S. Provisional Application No. 61/520,040, filed June 3, 2011, U.S. Provisional Application No. 61/494,683, filed June 8, 2011, and U.S. Provisional Application No. 61/555,712, filed November 4, 2011.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

This invention was made with Government Support under Agreement 01-HL 053793 awarded to Michael Simons by the National Institutes of Health, and Agreement R01-HL 098228 awarded to Christopher K. Breuer by the National Institutes of Health. The Government has certain rights in the invention.

FIELD OF THE INVENTION

The invention is generally related to the field of vascular stenosis and restenosis, more particularly to compositions and methods for the prevention and treatment of neointimal hyperplasia or the formation of tissue engineered vascular graft stenosis.

BACKGROUND OF THE INVENTION

Intimal or Neointima formation underlies a number of common vascular diseases, including vascular graft stenosis and restenosis after an angioplasty or stent. Despite decades of investigations, the origin of neointima still remains controversial with studies variously pointing to the role of medial smooth muscle cell (SMC) proliferation (Costa MA and Simon DI. Circulation. 111(17):2257 (2005)), vessel wall inflammation (Ohtani , et al. Circulation. 1 0(16):2444 (2004)) and adventitial angiogenesis (Khurana R, et al. Circulation. 110(16):2436 (2004)).

Neointimal stenosis followed by thrombosis is the major cause of synthetic vascular graft failure. Tissue engineered vascular grafts (TEVGs) offer many advantages to these synthetic grafts, but also have limitations of their own. TEVGs are typically prepared by seeding autologous cells onto a biodegradable polymeric tubular scaffold. The scaffold degrades by hydrolysis, ultimately leaving only the living vessel in the patient.

The methodology of seeding synthetic vascular grafts with autologous cells, however, is still problematic for many reasons. First, it requires an invasive procedure (biopsy) in addition to the need for a substantial period of time in order to expand the cells in culture that limited its clinical utility. This approach also faces the inherent difficulty in obtaining healthy autologous cells from diseased donors (Poh, et al., Lancet, 365:2122-24 (2005); Solan, et al., Cell Transplant, 14(7):481-8 (2005)). The use of cell culture also results in an increased risk of contamination and even the potential for dedifferentiation of the cultured cells. The use of autologous cells to seed the polymeric grafts also limits the off-the-shelf availability of tissue engineered vascular grafts, thereby limiting their overall clinical utility. TEVGs that do not require cell seeding would offer many therapeutic, economic, and safety advantages.

It is an object of the invention to provide compositions and methods for treating and preventing neointimal stenosis.

It is a further object of the invention to provide methods for increasing the patency of biodegradable, synthetic vascular grafts with or without using cell seeding.

It is a further object of the invention to provide a cell-free TEVG with improved patency and reduced graft stenosis.

SUMMARY OF THE INVENTION

The disclosed compositions and methods are based on the discovery that an endothelial-to mesenchymal transition (Endo-MT) of vascular endothelial cells into smooth muscle cells (SMC) contributes to neointimal stenosis. Endo-MT in blood vessels is initiated by transforming growth factor β (TGF ) signaling. In some embodiments, this TGF signaling is through TGF receptor I (TGFpRI) and SMAD2. Endo-MT is normally suppressed by ongoing fibroblast growth factor (FGF) signaling, which maintains Let- 7 microRNA expression, which in turn prevents the activation of TGFp, TGFpRl and SMAD2 expression. A method for treating or preventing neointimal stenosis by inhibiting or reversing Endo-MT is therefore disclosed. The method generally involves the use of a composition contains a TGF inhibitor, a SMAD2 inhibitor, an FGF receptor agonist, a Let-7 agonist, or a combination thereof to inhibit or prevent Endo-MT in blood vessels with damaged endothelium to prevent or inhibit neointimal stenosis. These compositions may be used to inhibit or prevent Endo-MT at the site of potential or actual neointima. For example, in some embodiments, the composition is coated on or incorporated into a vascular device, such as a vascular graft, balloon, or stent prior to

administration to a blood vessel of the subject. In other embodiments, the composition is administered directly to the subject, e.g., after administration of a vascular device or after diagnosis of a neointimal stenosis. In these embodiments, the composition is preferably administered locally to the site of actual or potential neointima formation.

Also disclosed are methods for increasing the patency of

biodegradable, synthetic vascular grafts by inhibiting Endo-MT. Cell-free tissue engineered vascular graft (TEVG) produced by this method are also disclosed. The methods involve either administering a composition containing a TGFp inhibitor, a SMAD2 inhibitor, an FGF Receptor agonist, a Let-7 agonist, or a combination thereof either to the subject receiving the TEVG or to the TEVG prior to implantation. The TEVGs are tubular, porous structures that allow for recruitment and integration of host cells into the graft that mediate remodeling and vascular neotissue formation. The TEVGs are biodegradable, which allows for the grafts to be completely replaced by forming neotissue as they degrade.

The disclosed TEVGs do not require cell seeding, avoiding many problems associated with seeding, including the need for an invasive procedure to obtain autologous cells, the need for a substantial period of time in order to expand the cells in culture, the inherent difficulty in obtaining healthy autologous cells from diseased donors, and an increased risk of contamination and the potential for dedifferentiation of the cells. The disclosed cell-free TEVGs therefore have a greater off-the-shelf availability and increased overall clinical utility. The cell-free TEVGs may be fabricated from biodegradable polymers using any known method. In one embodiment, the polymeric vascular grafts are fabricated from woven or non-woven sheets or felts or polymeric fibers. The polymers and fabrication methods are selected to produce vascular grafts with biomechanical properties, such as initial burst pressure, suture retention strength, elasticity and tensile strength, suitable for use as vascular conduits. Polymeric woven or non- woven sheets or felts may be further treated with polymeric sealants to modify the biomechanical properties of the graft and/or to control the total porosity and pore size distribution range of the vascular graft.

A composition containing a TGTGFp inhibitor, a SMAD2 inhibitor, an FGF Receptor agonist, a Let-7 agonist, or a combination thereof, may be administered in an effective amount to prevent, inhibit or reduce restenosis, thrombus or aneurysm formation in implanted polymeric vascular grafts. The composition may be administered prior to vascular graft implantation, at the same time as vascular graft implantation, following vascular graft implantation, or any combination thereof. In one embodiment, the composition is administered either locally or systemically from a controlled release formulation.

In a preferred embodiment, the composition is administered locally at the site of graft implantation using a controlled release formulation. In some embodiments, the composition is incorporated into or onto the polymeric vascular graft which functions as a controlled release formulation. The composition may be dispersed evenly throughout the polymeric vascular graft using any known suitable method. In another embodiment, the composition is encapsulated in a second polymeric matrix that is coated on or incorporated into the polymeric vascular graft. In some embodiments, the composition is encapsulated into microspheres, nanospheres, microparticles and/or microcapsules, and seeded into the porous vascular graft.

The cell-free TEVGs may be used as venous, arterial or artero- venous conduits for any vascular or cardiovascular surgical application. Exemplary applications include, but are not limited to, congenital heart surgery, coronary artery bypass surgery, peripheral vascular surgery and angioaccess. BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1 A- IF are bar graphs showing qRT-PCR mRNA expression (normalized fold expression) of TGFpl (Fig. 1 A), TGFpRl (Fig. IB), TGFpRII (Fig. 1C), SM a-actin (Fig. ID), FSP1 (Fig. IE), and Vimentin (Fig. IF) in control (sold bar) and FRS2 knockdown (shaded bar) HUAEC. *p<0.05; ***p<0.001 compared to control.

Figures 2A-2I are bar graphs showing qRT-PCR mRNA expression (normalized fold expression) of SM-calponin (Figs. 2A, 2D, 2G)₅

Fibronectin (Figs. 2B, 2E, 2H), and Vimentin (Figs. 2C, 2F, 21) in ECs treated with the TGFpRl inhibitor SB431542 (Figs. 2A-2C), transduced with the dominant negative TGFpRl construct TGFpRl K230R (Figs. 2D-2F), or treated with Smad2 shRNA (Figs. 2G-2I). **p<0.01; ***p<0.001; NS: not significant compared to control.

Figures 3A-3B are graphs showing qRT-PCR mRNA expression (relative mRNA level) of TGFpRl (Fig. 3A) and Smad2 (Fig. 3B) as a function of time (hr) after 10 μg ml actinomycin D (AcfD) in HUAEC treated with control (-·-) or FRS2 shRNA (-■-). Figures 3C-3D show alignment of let-7 sequences with the 3'ITRs of the human TGFpRl and Smad2. Figures 3E-3 J are bar graphs showing qRT-PCR miRNA expression (relative expression) of hsa-let~7a (Fig. 3E), hsa-let-7b (Fig. 3F), has-let-7c (Fig. 3G), hsa-let-7d (Fig. 3H), hsa-let-7e (Fig. 31) and let-7a (3J) in HUAEC treated with control (left bars) or FRS2 shRNA (right bars). Figures 3 -3P are plots showing qRT-PCR miRNA expression (relative expression) of let- 7b (Fig. 3K), let-7c (Fig. 3L), let-7d (Fig. 3M), let-7e (Fig. 3N), let-7f (Fig. 30), and let-7g (Fig. 3P) in El 0.5 wild-type (first row), FRS2a +/2F (second row), and FRS2a 2F/2F (third row) embryos. Each dot on the graphs represents one embryo.

Figure 4A is a graph showing qRT-PCR miRNA expression (relative mRNA level) of Lin28 in HUAEC 24 hr (rows 1 and 5), 36 hr (rows 2, and 6), 48 hours (rows 3 and 7) or 72 hours (rows 4 and 8) after transduction with an empty vector (rows 1-4) or a vector expressing lin28 (rowls 5-8). Figures 4B-4E are bar graphs showing qRT-PCR miRNA expression (relative mRNA level) of hsa-let-7b (Fig. 4B), has-let-7c (Fig. 4C), hsa-let-7i (Fig. 4D), and hsa-mir-98 (Fig. 4E) in HUAEC 24 hr (rows 1 and 5), 36 hr (rows 2, and 6), 48 hours (rows 3 and 7) or 72 hours (rows 4 and 8) after transduction with an empty vector (rows 1-4) or a vector expressing lin28 (rows 5-8). Figure 4F is an illustration of the let-7 sponge decoy. Figure 4G is a bar graphs showing qRT-PCR mRNA expression (relative mRNA level) of TGF RI (rows 1 and 2), Smad2 (rows 3 and 4), and SM-calponin (rows 5 and 6) in control (sold bars) and lin28 overexpressing (shaded bars) HUAEC. Figure 4H is a bar graphs showing qRT-PCR mRNA expression (relative mRNA level) of TGFpRI (rows 1 and 2), Smad2 (rows 3 and 4), SM- calponin (rows 5 and 6), and HMGA2 (rows 7 and 8) in control (solid bars) or let-7 sponge overexpressing (shaded bars) HUAEC. Figures 4I-4 are bar graphs showing qRT-PCR mRNA expression (relative mRNA level) of SM a-actin (Fig. 41), SM22a (Fig. 4J), and SM-calponin (Fig. 4 ) in control (rows 1 and 2)) or let-7 sponge overexpressing (rows 3 and 4) HUAEC untreated (-, rows 1 and 2) or treated with TGFp 1 (+, rows 2 and 4). Figure 4L is a bar graph showing qRT-PCR miRNA expression (relative mRNA level) of let-7b (rows 1 and 2) or let-7c (rows 3 and 4) in liver endothelial cells of mice injected intravenously with PBS (shaded bars) or a single injection of 2 mg/kg cholesterol formulated antagomir-let-7b/c (open bars) that were isolated at 6 days. n=5 mice in each group. Figure 4M is a bar graph showing qRT-PCR miRNA expression (relative mRNA level) of let-7a (rows 1 and 2), let-7d (rows 3 and 4), let-7e (rows 5 and 6), let-7f (rows 7 and 8), let-7g (rows 9 and 10), let-7i (rows 11 and 12), miR-98 (rows 13 and 14) in liver endothelial cells of mice injected intravenously with PBS (shaded bars) or a single injection of 2 mg kg cholesterol formulated antagomir-let- 7b/c (open bars) that were isolated at 6 days. n=5 mice in each group. Figure 4N is a bar graph showing qRT-PCR miRNA expression (relative mRNA level) of HMGA2 (rows 1 and 2), CDK6 (rows 3 and 4), CDC25A (rows 5 and 6), TGFpRl (rows 7 and 8), and Vimentin (rows 9 and 10) in liver endothelial cells of mice injected intravenously with PBS (shaded bars) or a single injection of 2 mg/kg cholesterol formulated antagomir-let-7b/c (open bars) that were isolated at 6 days. Figure 5 A is a bar graph showing qRT-PCR miRNA expression (relative mRNA level) of let-7b (open bars) and let-7c (shaded bars) in HUAEC 0 hrs (rows 1 and 5), 12 hrs (rows 2 and 6), 24 hrs (rows 3 and 7) and 30 hours (rows 4 and 8) after transduction with lentivirus vector expressing pre-Iet-7b (open bars) or pre-let-7c (shaded bars). qRT-PCR was performed for mature let-7 miRNAs. Figures 5B-5I are bar graphs showing qRT-PCR mRNA expression (relative mRNA level) of TGFpRI (Fig. 5B), Smad2 (Fig. 5C), FSP1 (Fig. 5D), Fibronectin (Fig. 5E), Vimentin (Fig. 5F), SM a-actin (Fig. 5G), SM22a (Fig 5H), and SM-calponin (Fig. 51) in control (rows 1 and 2) and FRS2 knockdown (rows 3 and 4) FIUAEC cells transduced with empty vector (rows 1 and 3) or a lenti viruses expressing let- 7c (rows 2 and 4). *p<0.05; **p<0.01; ***p<0.001 compared to control.

Figures 6A-6G are bar graphs showing qRT-PCR miRNA expression (relative mRNA level) of hsa-let-7a (Fig. 6A), hsa-let-7b (Fig. 6B), hsa-let- 7c (Fig. 6C), hsa-let-7d (Fig. 6D), hsa-let-7e (Fig. 6E), hsa-let-7f (Fig. 6F), and hsa-let-7g (Fig. 6G) in HUAEC 0 hrs (row 1), 6 hrs (row 2), and 9 hrs (row 3) after FGF2 treatment. Figures 6H-6M are bar graphs showing qRT- PCR miRNA expression (relative mRNA level) of hsa-let-7b (Fig. 6H), hsa- let-7c (Fig. 61), hsa-let-7e (Fig. 6 J), hsa-let-7f (Fig. 6K), hsa-let-7g (Fig. 6L), and hsa-mir-98 (Fig. 6M) in HUAEC 12 hrs (rows 1 and 4),18 hrs (row 2 and 5), and 30 hrs (row 3 and 6) after treatment with DMSO control (shaded bars) or U0126 (solid bars). Figures 6N-6Q are bar graphs showing qRT- PCR miRNA expression (relative mRNA level) of hsa-let-7a (Fig. 6N), hsa- let-7b (Fig. 60), hsa-let-7c (Fig. 6P), and hsa-let-7e (Fig. 6Q) in control (rows 1 and 2) and FRS2 knockdown (rows 3 and 4) HUAEC transduced with an empty vector (- rows 1 and 3) or with a constitutively active ERK (Ad-ME-LA) (+, rows 2 and 4).

Figures 7A-7C are plots showing qRT-PCR mRNA expression (relative mRNA level) of TGF l (Fig. 7 A), TGFpRI (Fig. 7B), and vimentin (Fig. 7C) in occluded TEVG at day 7 (row 1) and day 14 (row 2). Each dot on graph represents gene expression level in one TEVG; **p<0.01;

***p<0.001 compared to control. Figures 7D-7E are bar graphs showing TEVG stenosis rate (Fig. 7D) and serum IgGl ^g/ml) (Fig. 7E) in control (row 1) and sFGFRl-IIIc treated (row 2) mice. Data shown represents mean

± SD from 2 wells per group.

Figures 8A-8B are bar graphs showing the percentage of cells with co-localized LacZ and SM a-actin in patent (row 1) and occluded (row 2) neointimal cells following TEVG insertion in Tie2-Cre;RosaLacZ mice (Fig.

8A) and Cdh5-CreERT2; RosaLacZ mice (Fig. 8B), with the latter Cre activated by tamoxifen administration on day P2. Figures 8C-8E are bar graphs showing luminal diameter (mm) (Fig. 8C), stenosis rate (%) (Fig.

8D), and percentage of cells with co-localized LacZ and SM a-actin (Fig. 8E) in Tie2-CreXRosa26 mice treated with DMSO (row 1) or the TGFpRI inhibitor SB431542 (row 2) after TEVG implantation. Data are presented as mean ± SD; *p<0.05; **p<0.01; ***p<0.001.

Figures 9A-9J are bar graphs showing qRT-PCR mRNA expression

(relative mRNA level) of SM a-actin (Fig. 9A), SM22a (Fig. 9B), SM- calponin (Fig. 9C), SM-MHC (Fig. 9D), Myocardin (Fig. 9E), PDGFRa

(Fig. 9F), PDGFRp (Fig. 9G), Vimentin (Fig. 9H), NG2 (Fig. 91), and Runxl

(Fig. 9 J) in primary mouse endothelial cells transduced with adenovirus-GFP

(sold bars) or adenovirus-Cre (shaded bars) at 4 days. *p<0.05; **p<0.01;

***p<0.001.

Figures 1 OA-1 OF are bar graphs showing qRT-PCR mRNA expression (relative mRNA level) of TGFpRI (Fig. 10A), TGFpRII (Fig. 10B), SM a-actin (Fig. IOC), SM22a (Fig. 10D), SM-calponin (Fig. 10E), and Fibronectin (Fig. 10F) in control (row 1) or FRF2 2F (row 2), FRS2 4F (row 3), FRS2 6F (row 3), FGFR1 dominant negative (row 4), FGFR1 K562E (row 5), or FGFR1 K562EVT (row 6) mutant overexpressing HUAEC.

Figures 11 A-l II are bar graphs showing qRT-PCR mRNA expression (relative mRNA level) of TGFpRI (Fig. 11A), TGFpRII (Fig. 11 B), Smad2 (Fig. 11C), SM a-actin (Fig. 1 ID), Fibronectin (Fig. 1 IE), Vimentin (Fig. 1 IF), N-cadherin (Fig. 11G), ZEB1 (Fig. 11H)₅ or ZEB2

(Fig. Ill) in control (solid bars) and FRS2 knockdown (shaded bars) primary human mammary epithelial cells. Figures 1 lJ-11M are bar graphs showing qRT-PCR miRNA expression (relative mRNA level) of hsa-mir-200b (Fig. 11 J), hsa-mir-200c (Fig. UK), hsa-let-7b (Fig. 11L), hsa-let7c (Fig. 11M) in control (solid bars) and FRS2 knockdown (shaded bars) primary human mammary epithelial cells.

Figures 12A-12D are bar graphs showing qRT-PCR mRNA expression (relative mRNA level) of TGFpRl (Fig. 12A), Smad2 (Fig. 12B), COL1 Al (Fig. 12C), and SM a-actin (Fig. 12D) in control (solid bars) and FRS2 knockdown (shaded bars) foreskin cells. Figures 12E-12H are bar graphs showing qRT-PCR mRNA expression (relative mRNA level) of TGF RI (Fig. 12E), Smad2 (Fig. 12F), COL1A1 (Fig. 12G), and Vimentin (Fig. 12H) in control (solid bars) and FRS2 knockdown (shaded bars) atrial cells.

Figure 13 is an illustration of the FGF/TGFp signaling pathway involved in endothelial-to-mesenchymal (Endo-MT) transition. TGF activity through TGF RI promotes Endo-MT via SMAD2-dependent (smooth muscle cells) and SMAD2-indendent (fibroblasts) pathways.

TGF Rl and SMAD2 are inhibited by let-7, which is activated by FGF signaling through FGFR. As let-7 decreases, TGFP activity increases and Endo-MT.

Figures 14A to 14B are graphs showing absolute (Fig. 14 A) and fractional (Fig. 14B) release of SB-431542 from (■) tethered PLGA microparticles and (A) PCLA phase of a PGA-PCLA TEVG scaffold.

Figures 14C and 14D are bar graphs showing luminal diameter (mm) (Fig.

14C) and stenosis rate (%) of control microparticles (Fig. 14 A, bar I; Fig.

14B, bar 3), SB-431542 microparticles (Fig. 14A, bar 2; Fig. 14B, bar 4), control scaffold (Fig. 14D, bar 1), and SB-431542 scaffold (Fig. 14D, bar 2).

DETAILED DESCRIPTION OF THE INVENTION

I. Definitions

The term "vascular stenosis" refers to an abnormal narrowing in a blood vessel that occurs following an injury to the vessel wall (endothelium). In some embodiments, stenosis involves a reduction in the circumference of a lumen of 50% or more. The term "restenosis" refers to stenosis at a previously stenotic site. Restenosis, as used herein, encompasses occlusion.

Exemplary injuries that result in stenosis or restenosis include trauma to an atherosclerotic lesion (as seen with angioplasty or stent), a resection of a lesion (as seen with endarterectomy), an external trauma (e.g., a cross- clamping injury), or a surgical anastomosis.

The term "neointimal stenosis" refers abnormal narrowing in a blood vessel resulting from neointimal formation.

The term "neointima" refers to a new or thickened layer of intima (inner lining) formed in a blood vessel in response to signals from injured endothelial cells.

The term "TGFp inhibitor" as used herein refers to a composition that directly inhibits TGFP or TGFpRI expression, TGF or TGFpRI

bioavailability, binding of TGF to TGFpRI, or the binding of TGFpRI to SMAD2.

The term "SMAD2 inhibitor" as used herein refers to a composition that directly inhibits an activity of SMAD2, such as the phosphorylation of SMAD2 protein by TGFpRI, the translocation of SMAD2 to the nucleus, or the binding of SMAD2 to a DNA substrate.

The term "FGF receptor agonist" refers to a composition that directly promotes FGF signaling through an FGF receptor (FGFR). The agonist may be an FGF protein (e.g., natural or recombinant FGF), an expression vector encoding an FGF protein, or any fragment or variant thereof that activates FGFR signaling.

The term "Let-7 agonist" refers to a composition that promotes one or more activities of a Let-7 microRNA. The agonist may be a Let-7 miRNA or an expression vector encoding one or more Let-7 microRNA.

The term "vascular device" refers to a medical device administered to a blood vessel during a medical procedure. The term covers devices that may damage the vascular wall and cause neointimal stenosis. The term includes vascular grafts, angioplasty balloons, and vascular stents.

The term "vector" refers to a replicon, such as a plasmid, phage, or cosmid,. into which another DNA segment may be inserted so as to bring about the replication of the inserted segment. The vectors can be expression vectors. The term "expression vector" refers to a vector containing a gene construct in a form suitable for expression by a cell (e.g., operably linked to a transcriptional control element).

The term "operatively linked to" refers to the functional relationship of a nucleic acid with another nucleic acid sequence. Promoters, enhancers, transcriptional and translational stop sites, and other signal sequences are examples of nucleic acid sequences operatively linked to other sequences. For example, operative linkage of DNA to a transcriptional control element refers to the physical and functional relationship between the DNA and promoter such that the transcription of such DNA is initiated from the promoter by an RNA polymerase that specifically recognizes, binds to and transcribes the DNA.

The term "individual," "host," "subject," and "patient" are used interchangeably to refer to any individual who is the target of administration or treatment. The subject can be a vertebrate, for example, a mammal. Thus, the subject can be a human or veterinary patient.

The term "treat" or "treatment" refers to the medical management of a patient with the intent to cure, ameliorate, stabilize, or prevent a disease, pathological condition, or disorder. This term includes active treatment, that is, treatment directed specifically toward the improvement of a disease, pathological condition, or disorder, and also includes causal treatment, that is, treatment directed toward removal of the cause of the associated disease, pathological condition, or disorder. In addition, this term includes palliative treatment, that is, treatment designed for the relief of symptoms rather than the curing of the disease, pathological condition, or disorder; preventative treatment, that is, treatment directed to minimizing or partially or completely inhibiting the development of the associated disease, pathological condition, or disorder; and supportive treatment, that is, treatment employed to supplement another specific therapy directed toward the improvement of the associated disease, pathological condition, or disorder.

The term "prevent" does not require absolute forestalling of the condition or disease but can also include a reduction in the onset or severity of the disease or condition. Thus, if a therapy can treat a disease in a subject having symptoms of the disease, it can also prevent that disease in a subject who has yet to suffer some or all of the symptoms.

The term "inhibit" refers to a decrease in an activity, response, condition, disease, or other biological parameter. This can include but is not limited to the complete ablation of the activity, response, condition, or disease. This may also include, for example, a 10% reduction in the activity, response, condition, or disease as compared to the native or control level. Thus, the reduction can be a 10, 20, 30, 40, 50, 60, 70, 80, 90, 100%, or any amount of reduction in between as compared to native or control levels.

The term "therapeutically effective" means that the amount of the composition used is of sufficient quantity to ameliorate one or more causes or symptoms of a disease or disorder. Such amelioration only requires a reduction or alteration, not necessarily elimination.

The term "pharmaceutically acceptable" refers to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problems or complications commensurate with a reasonable benefit/risk ratio.

The term "small molecule" refers to a molecule, such as an organic or organometallic compound, with a molecular weight of less than 2,000 Daltons, more preferably less than 1,500 Daltons, most preferably less than 1,000 Daltons. The small molecule can be a hydrophilic, hydrophobic, or amphophilic compound.

The term "antibodies" refers to natural or synthetic antibodies that selectively bind a target antigen. The term includes polyclonal and monoclonal antibodies. In addition to intact immunoglobulin molecules, also included in the term "antibodies" are fragments or polymers of those immunoglobulin molecules, and human or humanized versions of immunoglobulin molecules that selectively bind the target antigen.

The term "copolymer" refers to a single polymeric material that is comprised of two or more different monomers. The copolymer can be of any form, such as random, block, graft, etc. The copolymers can have any end- group, including capped or acid end groups.

The term "biocompatible" refers to a material and any metabolites or degradation products thereof that are generally non-toxic to the recipient and do not cause any significant adverse effects to the subject.

The term "biodegradable" refers to a material that will degrade or erode under physiologic conditions to smaller units or chemical species that are capable of being metabolized, eliminated, or excreted by the subject.

The term "controlled release" or "modified release" refers to a release profile in which the active agent release characteristics of time course and/or location are chosen to accomplish therapeutic or convenience objectives not offered by conventional dosage forms such as solutions, suspensions, or promptly dissolving dosage forms. Delayed release, extended release, and pulsatile release and their combinations are examples of modified release.

The term "bioactive agent" or "active agent" refers to therapeutic, prophylactic, and/or diagnostic agents. It includes without limitation physiologically or pharmacologically active substances that act locally or systemically in the body. A biologically active agent is a substance used for, for example, the treatment, prevention, diagnosis, cure, or mitigation of disease or disorder, a substance which affects the structure or function of the body, or pro-drugs, which become biologically active or more active after they have been placed in a predetermined physiological environment.

Bioactive agents include biologically, physiologically, or pharmacologically active substances that act locally or systemically in the human or animal body. Examples can include, but are not limited to, small-molecule drugs, peptides, proteins, antibodies, sugars, polysaccharides, nucleotides, oligonucleotides, aptamers, siRNA, nucleic acids, and combinations thereof. "Bioactive agent" includes a single agent or a plurality of bioactive agents including, for example, combinations of two or more bioactive agents.

H. Compositions

A. TGFp and SMAD2 Inhibitors

As discussed above endothelial-to-mesenchymal transition (Endo- MT) is initiated in blood vessels after angioplasty, vascular graft, or other injury, by TGFp signaling. In some embodiments, this TGFp signaling is TGF RI- and SMAD2-dependent. Therefore, TGF inhibitors and SMAD2 inhibitors are disclosed for inhibiting, preventing, and/or reversing Endo-MT in blood vessels.

1. SB431542

In some embodiments, the TFGp or SMAD2 inhibitor is 4-[4-(l,3- Benzodioxol-5-yl)-5-{2-pyridinyl)-lH-imidazol-2-yl]-benzamide

(SB431542).

SB431542 inhibits the activity of transforming growth factor βΐ (TGF-β 1) activin receptor-like kinases (ALKs). It is a selective and potent inhibitor of the phylogenetically related subset of ALK-4 (activin type I receptor), ALK-5 (TGF RI), and ALK-7 (nodal type I receptor). SB431542 inhibits endogenous activin and TGF-β signaling but is without effect on the more divergent ALK-1, -2, -3, and -6 and hence BMP signaling.

Phosphorylation of Smad2 by ectopically expressed constitutively active ALK-4₅ ALK-5, and ALK-7 in transfected NIH 3T3 cells is completely abolished by SB431542 at 10 mM (Watabe, T., et al., J Cell Biol., 163, 1303 (2003)). In addition, the compound inhibits Hgand dependent activation of wild type ALK-4 and endogenous ALK-5 with an IC₅₀ of approximately 0.25 mM (Watabe, T., et al., J Cell Biol, 163, 1303 (2003)).

2. SB208

In some embodiments, the TFGp or SMAD2 inhibitor is 2-(5-Chloro- 2-fluorophenyl)-4-[(4-pyridyl)amino]pteridine (SB208). SB208 is a potent, orally active, ATP-competitive TGF- RI inhibitor (IC₅₀ = 49nM).

3. SB525334

In some embodiments, the TFGp or SMAD2 inhibitor is 6-[2-(l,l- Dimethylethyl)- 5 -(6-methyl-2-pyr idinyl)- 1 H-imidazol-4-yl] quinoxaline (SB525334). SB525334 is a selective inhibitor of TGF-pRI (IC50 = 14.3 nM). It inhibits TGF-βΙ -induced smad2/3 nuclear localization and TGF-βΙ- induced mRNA expression. 4. LY21S7299

In some embodiments, the TFGp or S AD2 inhibitor is 4-(2-(6- methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[l,2-b]pyrazol-3-yl)quinoline-6- carboxamide (LY2157299). LY2157299 is a selective kinase inhibitor for TGF-pRl with IC₅₀ of 86 nM. LY2157299 is well tolerated at doses of 40 mg and 80 mg.

5. EW-7203

In some embodiments, the TFGp or SMAD2 inhibitor is 3-((5- ([ 1 ,2,4]triazolo[ 1 ,5-a]pyridin-6-yl)-4-(6-methylpyridin-2-yl)thiazol-2- ylamino)methyl)benzonitrile (EW-7203). EW-7203 inhibits TGF-βΙ- induced Smad signaling and Endo-MT in mammary epithelial cells (Park CY, et al. Cancer Set 102(10): 1889-96 (2011)).

6. SM16

In some embodiments, the TFGp or SMAD2 inhibitor is 4-(5- (benzo[d] [ 1 ,3]dioxol-5-yl)-4-(6-methylpyridin-2-yl)- 1 H-imidazol-2- yl)bicyclo[2.2.2]octane-l -carboxamide (SM16). SM16 is a 430.5 MW AL 5/ALK4 kinase inhibitor that blocks TGF-β and activin-induced Smad2/3 phosphorylation.

7. Losartan

In some embodiments, the TFGp inhibitor is (2~butyl-4-chloro-l -

{ [2'-( 1 H-tetrazol-5-yl)biphenyl-4-yl]methyl } - 1 H-imidazol-5-yl)methanol (Losartan). Losartan (rlNN) is an angiotensin II receptor antagonist drug used mainly to treat high blood pressure that has also been shown to downregulate the expression of TGF-β types I and II receptors.

8. Competitive Binding Molecules

The SMAD pathway is the canonical signaling pathway that TGF-β family members signal through. In this pathway, TGF-β dimers bind to a type II receptor which recruits and phosphorylates a type I receptor. The type I receptor then recruits and phosphorylates a receptor regulated SMAD (R- SMAD).

Therefore, TGFp signaling can also be inhibited with molecules that competitively bind TGFp or TGFpRII and inhibit TGFp signaling. SMAD2 activity can also be inhibited with molecules that competitively bind TGFpRI or SMAD2 and inhibit SMAD2 phosphorylation, translocation, or binding to DNA substrates. Examples of such competitive binding molecules as antibodies, soluble receptors (ligand trap), and mutant ligands.

Antibodies that can be used in the disclosed compositions and methods include whole immunoglobulin (i.e., an intact antibody) of any class, fragments thereof, and proteins containing at least the antigen binding variable domain of an antibody. The variable domains differ in sequence among antibodies and are used in the binding and specificity of each particular antibody for its particular antigen. The variability is not usually evenly distributed through the variable domains of antibodies. It is typically concentrated in three segments called complementarity determining regions (CDRs) or hypervariable regions both in the light chain and the heavy chain variable domains. The more highly conserved portions of the variable domains are called the framework (FR). The variable domains of native heavy and light chains each comprise four FR regions, largely adopting a beta-sheet configuration, connected by three CDRs, which form loops connecting, and in some cases forming part of the beta-sheet structure. The CDRs in each chain are held together in close proximity by the FR regions and, with the CDRs from the other chain, contribute to the formation of the antigen binding site of antibodies. Therefore, the disclosed antibodies contain at least the CDRs necessary to bind TGFp, TGF RI, TGF RII, or SMAD2 and inhibit TGF signaling.

Techniques can also be adapted for the production of single-chain antibodies that bind TGF , TGF RI, TGFpRII, or SMAD2 and inhibit TGFp signaling. Methods for the production of single-chain antibodies are well known to those of skill in the art. A single chain antibody can be created by fusing together the variable domains of the heavy and light chains using a short peptide linker, thereby reconstituting an antigen binding site on a single molecule. Single-chain antibody variable fragments (scFvs) in which the C- terminus of one variable domain is tethered to the N-terminus of the other variable domain via a 15 to 25 amino acid peptide or linker have been developed without significantly disrupting antigen binding or specificity of the binding. The linker is chosen to permit the heavy chain and light chain to bind together in their proper conformational orientation. Divalent single- chain variable fragments (di-scFvs) can be engineered by linking two scFvs. This can be done by producing a single peptide chain with two VH and two VL regions, yielding tandem scFvs. ScFvs can also be designed with linker peptides that are too short for the two variable regions to fold together (about five amino acids), forcing scFvs to dimerize. This type is known as diabodies. Diabodies have been shown to have dissociation constants up to 40-fold lower than corresponding scFvs, meaning that they have a much higher affinity to their target. Still shorter linkers (one or two amino acids) lead to the formation of trimers (triabodies or tribodies). Tetrabodies have also been produced. They exhibit an even higher affinity to their targets than diabodies.

Soluble TGFp receptors, such as a soluble TGFpRII receptor, may also be used to bind free TGFp and prevent activation of TGFp signaling. Soluble TGFpRI receptor may also be used to bind free SMAD2 and prevent phosphorylation of SMAD2. Soluble receptors are generally chimeric fusion proteins containing the extracellular domain of the receptor fused to the Fc portion of an immunoglobulin.

A mutant TGFp ligands that bind TGFpRII without activating receptor signaling may be used to compete with endogenous TGFp and inhibit TGFpRI signaling. A mutant SMAD2 that binds TGFpRI without being phosphorylated and activating downstream targets may be used to compete with endogenous TGFPRI for binding to endogenous SMAD2.

B. FGF Receptor agonists

FGF signaling suppresses Endo-MT. Therefore, FGF agonists are disclosed for use in the disclosed compositions and methods. Therefore, FGF Receptor agonists are disclosed for use in the disclosed compositions and methods. Any FGF receptor agonists, i.e., agents composition that directly promotes FGF signaling through an FGF receptor (FGFR) can be used in the disclosed compositions and methods.

In some embodiments, the FGF Receptor agonist is natural, synthetic, or recombinant FGF peptide or protein that can bind and activate FGF

Receptor signaling in an endothelial cell, such as a human endothelial cell. The FGF protein is preferably human. Recombinant human FGF -2 proteins are commercially available from, for example, INVITROGEN (Grand Island, NY) and R&D SYSTEMS (Minneapolis, MN). Other examples of FGF proteins which are FGF agonists include FGF1, FGF4 and FGF-5, however, over 20 FGF family proteins (FGF 1-14 and FGF 1-23) have been identified, most of which bind to one or more of the 4 FGF receptors. Reviewed in Itoh, et al._s Trends in Genetics, 20(1 l):563-9 (2004).

Expression vectors encoding an FGF protein, or fragment thereof, that binds and activates FGF Receptor may also be used. The expression vector may contain a nucleic acid encoding an FGF agonist operably linked to an expression control sequence.

Small molecule FGF Receptor agonist that may be used in the disclosed compositions and methods are described in U.S. Patent Publication No. 2009/0069368 by Bono, et al. Other FGF Receptor agonists include agonistic antibodies specific for FGF receptors, described for example in Malavaud, et al„ Oncogene, 23:6769-6778 (2004).

C. Let-7 microRNA agonists

FGF signaling suppresses Endo-MT by maintaining Let-7 microRNA expression, which prevents the activation of TGFp, TGFpRl and SMAD2. Therefore, Let-7 agonists are disclosed for use in the disclosed compositions and methods.

In preferred embodiments, the Let-7 agonist is a Let-7 miRNA or a polynucleotide encoding a Let-7 miRNA. In some embodiments, the Let-7 agonist is a pri-miRNA, pre-miRNA, mature miRNA, or a fragment or variant thereof effective in gene silencing, e.g., silencing TGFBRI gene expression. In other embodiments, the let-7 miRNA is an RNA interference- inducing (RNAi) molecule including, but not limited to, a siRNA, dsRNA, stRNA, shRNA₅ or gene silencing variants thereof. In alternative

embodiments the let-7 miR A is an agent which binds and inhibits an RNA transcript comprising a let-7 target sequence. Examples of such agents include, but are not limited to a small molecule, protein, antibody, aptamer, ribozyme, nucleic acid or nucleic acid analogue. In some embodiments, the Let-7 miRNA is human let-7al, let-7a2, let-7a4, let-7b, let-7c, let-7d, let-7d, let-7fl, let-7f2, let-7g, let-7i, or mir-98. Of these let-7 family members, Let-7b and Let-7c have the best sequence match with TGFpRl . The following are sequences for the human let-7 family members. Also disclosed are conservative variants of these sequences having 1, 2, 3, 4, 5, or 6 substitutions, deletions, or insertions

<img file="WO2012167261A2_D0001.tif" /> In some embodiments, the Let-7 agonist is a vector encoding one or more let-7 miRNA operably linked to a transcription control element. For example, genes inserted in viral and retroviral systems usually contain promoters and/or enhancers to help control the expression of the desired gene product. A promoter is generally a sequence or sequences of DNA that function when in a relatively fixed location in regard to the transcription start site. A promoter contains core elements required for basic interaction of RNA polymerase and transcription factors, and may contain upstream elements and response elements. Enhancer generally refers to a sequence of DNA that function at no fixed distance from the transcription start site and can be either 5' or to the transcription unit. Furthermore, enhancers can be within an intron as well as within the coding sequence itself. They are usually between 10 and 300 bp in length, and they function in cis. Enhancers function to increase transcription from nearby promoters.

In some embodiments, the promoter is inducible. In other

embodiments, the promoter is a constitutive to maximize expression of the region of the transcription unit to be transcribed. In some embodiments, the promoter is tissue-specific, e.g., expressed only in vascular endothelial cells.

D. Pharmaceutical Compositions

Pharmaceutical compositions containing therapeutically effective amounts of a TGF inhibitor, a SMAD2 inhibitor, an FGF Receptor agonist, a Let-7 agonist, or a combination thereof optionally in a pharmaceutically acceptable carrier/excipient are disclosed.

/. Formulations for parenteral administration

In one embodiment, the pharmaceutical composition is administered in an aqueous solution by parenteral injection. The formulation may also be in the form of a suspension or emulsion. In general, pharmaceutical compositions are provided including effective amounts of a TGFP inhibitor, a SMAD2 inhibitor, an FGF Receptor agonist, a Let-7 agonist, or a combination thereof, and optionally include pharmaceutically acceptable diluents, preservatives, solubilizers, emulsifiers, adjuvants and/or carriers. Such compositions include diluents sterile water, buffered saline of various buffer content (e.g., Tris-HCI, acetate, phosphate), pH and ionic strength; and optionally, additives such as detergents and solubilizing agents (e.g., TWEEN® 20, TWEEN® 80, Polysorbate 80), anti-oxidants (e.g., ascorbic acid, sodium metabisulfite), and preservatives (e.g., Thimersol, benzyl alcohol) and bulking substances (e.g., lactose, mannitol). Examples of non- aqueous solvents or vehicles are propylene glycol, polyethylene glycol, vegetable oils, such as olive oil and corn oil, gelatin, and injectable organic esters such as ethyl oleate. The formulations may be lyophilized and redissolved/resuspended immediately before use. The formulation may be sterilized by, for example, filtration through a bacteria retaining filter, by incorporating sterilizing agents into the compositions, by irradiating the compositions, or by heating the compositions.

2. Controlled delivery polymeric matrices In one embodiment, the pharmaceutical composition containing a TGFTGFp inhibitor, a SMAD2 inhibitor, an FGF Receptor agonist, a Let-7 agonist, or a combination thereof is administered systemically or locally using controlled release formulations. In a preferred embodiment, the pharmaceutical composition is administered locally at the site of a vascular device using a controlled release formulation.

In one embodiment, the pharmaceutical composition is coated on or incorporated into a polymeric vascular graft which functions as a controlled release formulation. The pharmaceutical composition may be dispersed throughout the polymeric vascular graft using any known suitable method. For example, the pharmaceutical composition is may be added to the polymeric scaffold during fabrication by adding it to the polymer solution or emulsion or during the fabrication of a polymeric textile, such as by an electro spinning process. Additionally, or alternatively, the pharmaceutical composition may be added to the polymeric graft following fabrication. In some embodiments, the pharmaceutical composition is localized to either the exterior or the lumen of the tubular polymeric vascular graft.

In another embodiment, the pharmaceutical composition may be encapsulated in a polymeric matrix that is either administered to the site of actual or potential neointimal stenosis or incorporated into the polymeric vascular graft. In some embodiments, the pharmaceutical composition is encapsulated into microspheres, nanospheres, microparticles and/or microcapsules. The matrix can be in the form of microparticles such as microspheres, where the active agent is dispersed within a solid polymeric matrix or microcapsules, where the core is of a different material than the polymeric shell, and the active agent is dispersed or suspended in the core, which may be liquid or solid in nature. Unless specifically defined herein, microparticles, microspheres, and microcapsules are used interchangeably. Alternatively, the polymer may be cast as a thin slab or film, ranging from nanometers to four centimeters, a powder produced by grinding or other standard techniques, or even a gel such as a hydrogel, and used as a coating for the vascular graft.

Either non-biodegradable or biodegradable matrices can be used for delivery of the pharmaceutical composition, although biodegradable matrices are preferred. These may be natural or synthetic polymers, although synthetic polymers are preferred due to the better characterization of degradation and release profiles. The polymer is selected based on the period over which release is desired. In some cases linear release may be most useful, although in others a pulse release or "bulk release" may provide more effective results. The polymer may be in the form of a hydrogel (typically in absorbing up to about 90% by weight of water), and can optionally be crosslinked with multivalent ions or polymers.

The matrices can be formed by solvent evaporation, spray drying, solvent extraction and other methods known to those skilled in the art.

Bioerodible microspheres can be prepared using any of the methods developed for making microspheres for drug delivery.

3. Formulations for enteral administration Bioactive agents that are not peptides or polypeptides can also be formulated for oral delivery. Oral solid dosage forms are known to those skilled in the art. Solid dosage forms include tablets, capsules, pills, troches or lozenges, cachets, pellets, powders, or granules or incorporation of the material into particulate preparations of polymeric compounds such as polylactic acid, polyglycolic acid, etc. or into liposomes. Such compositions may influence the physical state, stability, rate of in vivo release, and rate of in vivo clearance of the present proteins and derivatives. ^Liposomal or polymeric encapsulation may be used to formulate the compositions. In general, the formulation will include the active agent and inert ingredients which protect peptide in the stomach environment, and release of the biologically active material in the intestine.

Another embodiment provides liquid dosage forms for oral administration, including pharmaceutically acceptable emulsions, solutions, suspensions, and syrups, which may contain other components including inert diluents; adjuvants such as wetting agents, emulsifying and suspending agents; and sweetening, flavoring, and perfuming agents.

Controlled release oral formulations may be desirable. Non- polypeptide bioactive agents can be incorporated into an inert matrix which permits release by either diffusion or leaching mechanisms, e.g., films or gums. Slowly disintegrating matrices may also be incorporated into the formulation. Another form of a controlled release is one in which the drug is enclosed in a semipermeable membrane which allows water to enter and push drug out through a single small opening due to osmotic effects. For oral formulations, the location of release may be the stomach, the small intestine (the duodenum, the jejunem, or the ileum), or the large intestine. Preferably, the release will avoid the deleterious effects of the stomach environment, either by protection of the active agent (or derivative) or by release of the active agent beyond the stomach environment, such as in the intestine. To ensure full gastric resistance an enteric coating (i.e, impermeable to at least pH 5.0) is preferred. Examples of the more common inert ingredients that are used as enteric coatings are cellulose acetate trimellitate (CAT), hydroxypropylmethylcellulose phthalate (HPMCP), HPMCP 50, HPMCP 55, polyvinyl acetate phthalate (PVAP), Eudragit L30D, Aquateric, cellulose acetate phthalate (CAP), Eudragit L, Eudragit S, and Shellac. These coatings may be used as mixed films or as capsules such as those available from Banner Pharmacaps.

4. Drug Eluting Stents

The pharmaceutical composition containing a TGFp inhibitor, a SMAD2 inhibitor, an FGF Receptor agonist, a Let-7 agonist, or a combination thereof, may also be released from a drag-eluting stent. A typical drug-eluting stent is a peripheral or coronary stent (a scaffold) placed into narrowed, diseased peripheral or coronary arteries that slowly releases a drug to block cell proliferation. The disclosed stent can contain a TGFp inhibitor, a SMAD2 inhibitor, an FGF Receptor agonist, a Let-7 agonist, or a combination thereof instead of, or in addition to, a drug that blocks cell proliferation.

Drug-eluting stents have three parts: a stent platform, a coating, and a drug. The stent itself is generally an expandable metal alloy framework. Many drug-eluting stents are based on a bare-metal stent (BMS). The stents have elaborate mesh-like designs to allow expansion, flexibility and in some cases the ability to make/enlarge side openings for side vessels. A coating, typically of a polymer, holds and elutes (releases) the drug into the arterial wall by contact transfer. Coatings are typically spray coated or dip coated. There can be one to three or more layers in the coating e.g. a base layer for adhesion, a main layer for holding the drug, and sometimes a top coat to slow down the release of the drug and extend its effect.

The main purpose of the drug is to inhibit neointimal growth which would cause restenosis. Existing drugs attempt to block proliferation of smooth muscle cells (SMC). The disclosed compositions containing a TGFp inhibitor, a SMAD2 inhibitor, an FGF Receptor agonist, a Let-7 agonist, or a combination thereoff, to inhibit Endo-MT of endothelial cells into SMC. Therefore, these compositions may also be used in combination with antiproliferative drugs for a combinatorial effect. Immunosuppressive and antiproliferative drugs may also be included.

5. Dosage

In one embodiment, the TGFp TGFp inhibitor, a SMAD2 inhibitor, an FGF Receptor agonist, a Let-7 agonist, or a combination thereof is administered in a dose equivalent to parenteral administration of about 0.1 ng to about 100 g per kg of body weight, about 10 ng to about 50 g per kg of body weight, about 100 ng to about 1 g per kg of body weight, from about ^g to about 100 mg per kg of body weight, from about 1 g to about 50 mg per kg of body weight, from about 1 mg to about 500 mg per kg of body weight; and from about 1 mg to about 50 mg per kg of body weight.

Alternatively, the amount of pharmaceutical composition administered to achieve a therapeutic effective dose is about 0.1 ng, 1 ng, 10 ng, 100 ng, 1 μ , 10 μ&amp; 100 g, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg, 19 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, 500 mg per kg of body weight or greater.

Area under the curve (AUC) refers to the area under the curve that tracks the serum concentration (nmol/L) of the TGFTGFp inhibitor, a SMAD2 inhibitor, an FGF Receptor agonist, a Let-7 agonist, or a

combination thereof over a given time following the IV administration of the reference standard. By "reference standard" is intended the formulation that serves as the basis for determination of the total dose to be administered to a human subject to achieve the desired positive effect, i.e., a positive therapeutic response that is improved with respect to that observed without administration of the pharmaceutical composition. In a preferred

embodiment, the dose of the TGF inhibitor, Let-7 agonist, or combination thereof provides a final serum level of TTGFp inhibitor, a SMAD2 inhibitor, an FGF Receptor agonist, a Let-7 agonist, or a combination thereof of about 100 ng/ml to about 1000 ng/ml, about 1100 ng/ml to about 1450 ng/ml, 100 ng/ml to about 250 ng ml, about 200 ng/ml to about 350 ng/ml, about 300 ng/ml to about 450 ng/ml, about 350 ng/ml to about 450 ng/ml, about 400 ng/ml to about 550 ng/ml, about 500 ng/ml to about 650 ng/ml, about 600 ng ml to about 750 ng/ml, about 700 ng/ml to about 850 ng/ml, about 800 ng/ml to about 950 ng/ml, about 900 ng/ml to about 1050 ng/ml, about 1000 ng/ml to about 1150 ng/ml, about 100 ng/ml to about 1250 ng/ml, about 1200 ng ml to about 1350 ng/ml, about 1300 ng/ml to about 1500 ng/m. In specific embodiments, the serum level of the TGF inhibitor, a SMAD2 inhibitor, an FGF Receptor agonist, a Let-7 agonist, or a combination thereof is about 100 ng/ml, 250 ng/ml, 300 ng/ml, 350 ng/ml, 360 ng/ml, 370 ng ml, 380 ng/ml, 390 ng/ml, 400 ng/ml, 410 ng/ml, 420 ng/ml, 430 ng/ml, 440 ng/ml, 450 ng/ml, 500 ng/ml, 750 ng/ml, 900 ng/ml, 1200 ng/ml, 1400 ng/ml, or 1600 ng/ml. Pharmaceutical formulations can be designed for immediate release, sustained release, delayed release and/or burst release of one or more active agents in a therapeutically effective amount. In a preferred embodiment, the formulation provides an initial burst release of a "loading dosage", followed by a sustained release to maintain the therapeutically effective dosage. This can be accomplished using a delayed and/or extended release formulation. HI. Methods for inhibiting neointima stenosis

Methods are disclosed for inhibiting neointima stenosis. In some embodiments, the neointima stenosis results from injury to the vascular wall (endothelium) after a medical procedure, such as angioplasty, vascular graft implantation, or stent placement. The method involves inhibiting the endothelial to mesenchymal transition (Endo-MT) of vascular endothelial cells into smooth muscle cells (SMC). FGF signaling suppresses Endo-MT by maintaining Let-7 microRNA expression, which prevents the activation of TGFp, TGFpRl and SMAD2 expression. Therefore, the disclosed method involves the use of a composition containing a TGFp inhibitor, a SMAD2 inhibitor, an FGF Receptor agonist, a Let-7 agonist, or a combination thereof to inhibit Endo-MT at the site of actual or potential neointima formation.

In some embodiments, the composition is coated on or incorporated into a vascular device, such as a vascular graft, angioplasty balloon, or vascular stent prior to its use. The composition may coated on or

incorporated into the vascular device using any known suitable method. The composition may be encapsulated in the form of microspheres, nanospheres, microparticies and/or microcapsules, and seeded on or into the vascular device.

In other embodiments, the composition is administered directly to the subject before, during, or after a medical procedure that may damage a vascular wall. In these embodiments, the composition is preferably administered locally to the site of actual or potential neointima formation.

A. Administration

In some embodiments, a pharmaceutical composition containing a TGF inhibitor, a SMAD2 inhibitor, an FGF Receptor agonist, a Let-7 agonist, or a combination thereof is administered to a subject receiving a vascular device in an effective amount to prevent, inhibit or reduce neointimal stenosis. The precise dosage will vary according to a variety of factors such as the nature of the compound being administered, the route of administration, and subject-dependent variables (e.g., age, etc.).

The pharmaceutical composition may be administered systemically or locally at the site of vascular graft implantation. The compositions may be administered prior to vascular device implantation, at the same time as vascular device implantation, following vascular device implantation, or any combination thereof. In one embodiment, the composition is administered either locally or systemically from a controlled release formulation. The composition may be administered separately from additional bioactive agents or may be co-administered.

Pharmaceutical compositions containing a TGFp inhibitor, a SMAD2 inhibitor, an FGF Receptor agonist, a Let-7 agonist, or a combination thereof may be administered by parenteral (intramuscular, intraperitoneal, intravenous (IV) or subcutaneous injection), transdermal (either passively or using iontophoresis or electroporation), or transmucosal (nasal, vaginal, rectal, or sublingual) routes of administration. The compositions can be formulated in dosage forms appropriate for each route of administration. Compositions containing bioactive agents that are not peptides or polypeptides can additionally be formulated for enteral administration.

IV. Methods for promoting patency of biodegradable, synthetic vascular grafts

The patency of biodegradable, synthetic vascular grafts may be increased using a composition that inhibits Endo-MT. Therefore, a method for promoting patency of a biodegradable, synthetic vascular graft is disclosed that involves administering a composition that inhibits Endo-MT to the graft or to the subject prior to or after implantation. Also disclosed is a cell-free tissue engineered vascular graft (TEVG) produced by this method.

Suitable Endo-MT inhibitors include TGFTGFP inhibitor, a SMAD2 inhibitor, an FGF Receptor agonist, a Let-7 agonist, or a combination thereof. The administration of Endo-MT inhibitors increases the patency of the biodegradable, synthetic vascular grafts. The disclosed biodegradable, synthetic vascular grafts do not require cell seeding to maintain patency of the grafts. This is advantageous, because it avoids problems associated with cell seeding, including the need for an invasive procedure to obtain autologous cells, the need for a substantial period of time in order to expand the cells in culture, the inherent difficulty in obtaining healthy autologous cells from diseased donors, and an increased risk of contamination and the potential for dedifferentiation of the cells. The disclosed biodegradable, synthetic vascular grafts therefore have a greater the off-the-shelf availability and increased overall clinical utility.

A. Polymeric vascular grafts

The disclosed polymeric vascular grafts are typically tubular porous conduits fabricated using biodegradable polymers. The pores in the polymeric vascular grafts allow for recruitment and integration of host cells into the graft. It is believed that recruited host cells mediate outward vascular tissue remodeling and vascular neotissue formation. Unlike synthetic vascular grafts that are currently in clinical use, the disclosed polymeric vascular grafts are biodegradable, which allows for the grafts to become replaced by forming neotissue as they degrade. Thus, the disclosed polymeric vascular grafts offer growth potential that is not possible with currently used synthetic vascular grafts.

The disclosed grafts are preferably substantially tubular in shape with a round or substantially round cross section. The tubular grafts have a lumen extending throughout the length of the graft. The grafts may be of any appropriate length and diameter that is suitable for the intended surgical use of the graft. Typically, the graft should be slightly longer than the length of artery or vein that is to be replaced.

The porous polymeric vascular grafts may be fabricated using any appropriate method, such as melt processing, solvent processing, leaching, foaming, extrusion, injection molding, compression molding, blow molding, spray drying, extrusion coating, and spinning of fibers with subsequent processing into woven or non-woven constructs. Pores in the graft may be derived by any suitable method, including salt leaching, sublimation, solvent evaporation, spray drying, foaming, processing of the materials into fibers and subsequent processing into woven or non-woven devices. Preferably, the pores of the device are between 5 μηι and 500 μηι, more preferably between 5 μηι and 250 μιη, more preferably between 5 μηι and 100 μιη, in diameter.

In some embodiments, the grafts are formed from a felt or sheet like material of the polymer that can be formed into a tubular conduit. For example the device could be fabricated as a nonwoven, woven or knitted structure from extruded polymeric fibers. The polymeric sheet may be formed using any textile construction, including, but not limited to, weaves, knits, braids or filament windings. Any suitable method, such as

electrospinning, may be used to fabricate the nonwoven or woven polymeric textile.

The polymers and fabrication methods selected to fabricate the polymeric vascular grafts are suitable to produce grafts with biomechanical properties suitable for use as vascular conduits. Biomechanical properties that are important for vascular graft function include initial burst pressure, suture retention strength and elasticity, in some embodiments, the initial burst pressure of the polymeric vascular graft is between about 1,500 mmHg and about 4,500 mmHg, preferably between about 2,000 mmHg and about 4,500 mmHg. In another embodiment, the polymeric vascular grafts possess suture retention strengths between about 1 N and about 5 N, preferably between about 2 N and about 4 N. In another embodiment, the intrinsic elasticity of the vascular grafts is between about 10 MPa and about 50 MPa, preferably between about 15 MPa and about 40 MPa. In another embodiment, the initial tensile strength of the vascular grafts is between about 1 MPa and about 10 MPa, preferably between about 3 MPa and about 6 MPa.

1. Biodegradable polymers

The biodegradable, synthetic vascular grafts may be fabricated using any known biodegradable polymer, co-polymer, or mixture thereof. Many suitable biodegradable polymers are known in art.

Examples of preferred biodegradable polymers include synthetic polymers that degrade by hydrolysis such as poly(hydroxy acids), such as polymers and copolymers of lactic acid and glycolic acid, polyanhydrides, poly(ortho)esters, polyesters, polyurethanes, poly(butic acid), poly(valeric acid), poly(caprolactone), poly(hydroxyalkanoates), and poly(lactide-co- caprolactone). The foregoing materials may be used alone, as physical mixtures (blends), or as co-polymers. In a preferred embodiment, the biodegradable, synthetic vascular grafts are fabricated from polyglycolic acid or poly-L-lactic acid.

2. Sealants

Synthetic vascular grafts fabricated from nonwoven, woven or knitted sheets or felts of biodegradable polymers may be further treated with polymeric sealants. The polymeric sealants function to modify the biomechanical properties of the vascular grafts, such as tensile strength and elasticity. Polymeric sealants may also be used to control the total porosity and pore size distribution range of the vascular graft.

Polymeric sealants for the disclosed biodegradable synthetic vascular grafts may be any biodegradable polymer, including, but not limited to, the list of biodegradable polymers listed above. In one embodiment, the polymeric sealant is a copolymer of poly(s-caprolactone) and poly(L- lactide). The copolymer can be at a ratio from 5:95 to 95:5, preferably from 30:70 to 70:30, more preferably from 40:60 to 60:40, most preferably about 50:50.

Polymeric sealants may be added to tubular synthetic grafts dissolved in an appropriate solvent to allow for the sealant to penetrate the nonwoven, woven or knitted sheet or felt of biodegradable polymers forming the graft. The polymeric sealant may then be quickly transformed from liquid to solid phase by lowering the temperature of the graft. Solvents may then be removed by an appropriate technique, such as lyophilization.

C. Additional bioactive agents

Additional bioactive agents that promote vascular graft adaptation may also be administered. Suitable bioactive agents or drugs include, but are not limited to: anti-thrombogenic agents, such as heparin, heparin derivatives, urokinase, and PPack (dextrophenylalanine proline arginine chloromethylketone; anti-proliferative agents, such as enoxaprin, angiopeptin, hirudin, acetylsalicylic acid, paclitaxel, 5-fluorouracil, cisplatin, vinblastine, vincristine, epothilones, endostatin, angiostatin and thymidine kinase inhibitors; anesthetic agents, such as lidocaine, bupivacaine, and ropivacaine; anti-coagulants, such as D-Phe-Pro-Arg chloromethyl keton, RGD peptide-containing compounds, heparin, antithrombin compounds, platelet receptor antagonists, anti-thrombin antibodies, anti-platelet receptor antibodies, aspirin, prostaglandin inhibitors, platelet inhibitors and tick antiplatelet peptides; cholesterol-lowering agents; vasodilating agents; and agents which interfere with endogenous vascoactive mechanisms.

D. Uses for biodegradable, synthetic vascular grafts

The disclosed biodegradable, synthetic vascular grafts may be used as venous, arterial or artero- venous conduits for any vascular or cardiovascular surgical application. Exemplary applications include, but are not limited to, congenital heart surgery, coronary artery bypass surgery, peripheral vascular surgery and angioaccess.

Vascular bypass grafting is most commonly performed for the treatment of vessel stenosis. However, vascular grafts are also used for the treatment of other conditions such as arterial aneurysm or chronic renal failure (as access for hemodialysis). Vascular grafting can be performed by conventional surgery or endovascular techniques.

Coronary artery bypass grafting (CABG) is one example of vascular bypass surgery. With this procedure, a bypass graft is used to bypass the coronary artery distal to the site of stenosis or occlusion. When a vein graft is used, one end is anastomosed to the aorta and the other end is anastomosed to the coronary artery beyond the stenosis or occlusion. When an arterial graft is used, the proximal end is left undisturbed (thus preserving the artery's normal blood inflow) and the distal end is anastomosed to the coronary artery beyond the stenosis or occlusion.

Typically, an anastomosis (i.e., the surgical union of tubular parts) between the in situ artery or vein and the synthetic graft is created by sewing the graft to the in situ vessel with suture. Commonly used suture materials include proline (extruded polypropyline) and ePTFE. EXAMPLES

Example 1: Basal FGF signaling suppresses TGFp-mediated Endo-MT

Materials and Methods

Cell culture and reagents

Human 293T Tl 7 cells (ATCC CRL- 11268) were maintained in

Dulbecco's modified Eagle's medium (Gibco) with 10% fetal bovine serum (Invitrogen) and penicillinstreptomycin (Gibco). Primary human mammary epithelial cells (HuMEC, Invitrogen), were maintained in HuMEC basal serum free medium with HuMEC supplement (Invitrogen 12754-016) and bovine pituitary extract (Invitrogen 13028-014). Human foreskin cells (ATCC CRL-1079Sk) were maintained in Minimum Essential Medium (ATCC) with 10% fetal bovine serum (Hyclone), β-mercaptoethanol

(Sigma), and penicillin-streptomycin (Gibco). Primary human atrial cells (passage 3-5; gift from Y. Qyang, Yale University School of Medicine) were maintained in Dulbecco's modified Eagle's medium (Gibco) with 10% fetal bovine serum (Invitrogen), L-glutamine (Gibco), Sodium pyruvate (Gibco), Non-essential amino acid (Gibco), and penicillin- streptomycin (Gibco).

HUAEC (human umbilical artery endothelial cells, passage 5-10, Lonza) were cultured in EBM-2 supplemented with EGM-2-MV bullet kit (Lonza). HUVEC (human umbilical vein endothelial cells, passage 3-7, Yale Vascular Biology and Therapeutics) were cultured in Ml 99 with ECGS, supplemented with 20% FBS (Sigma), L-glutamine (Gibco), and penicillin-streptomycin (Gibco). Culture vessels were coated with 0.1% gelatin (Sigma) for 30 min at 37°C immediately prior to cell seeding. Primary mouse endothelial cells were isolated from the heart using rat anti-mouse CDS 1 antibody and

Dynabeads (Invitrogen) as previously described (Partovian C, et al. Mol Cell. 32(1): 140 (2008)).

Antibodies used for immunodetection of proteins

The following antibodies were used for flow cytometry (F), immunoblotting (IB), immunofluorescence (IF), or immunohistochemistry (IHC): antibodies to 5G11 (IB; Mood K, et al. J Biol Chem. 277(36):33196 (2002)), β-galactosidase (Ab9361, Abeam; IF), Calponin, clone hCP (C- 2687, Sigma; IB), CD31 (sc-1506, Santa Cruz; IB), CD31 (Ab28364-100, Abeam; IF), CD31 (550274, BD Pharmingen; EC isolation), CD31-APC (FAB3567A, R&amp;D; F), FLAG (F1804, Sigma; IB), FRS2 (H-91, Santa Cruz; IB), Lin28A (3695, Cell Signaling; IB), N-cadherin (610920, BD

Transduction Laboratories; IB), Smad2 (3122, Cell Signaling; IB), p-Smad2 (Ser465/467) (3108, Cell Signaling; IB), SM22 alpha (abl4106, Abeam; IB), smooth muscle a-actin clone 1 A4 (A2547, Sigma; IB), smooth muscle - actin (M0851, Dako; IF), TGFp (Ab53169, Abeam; IHC), TGFpRl (sc-398, Santa Cruz; IB), β-tubulin (T7816, Sigma; IB), VE-cadherin (C-19, Santa Cruz; IB, IF), Vimentin clone V9 (V6630, Sigma; IB), VEGFR2 (2479, Cell Signaling; IB), ZEB1 (HPA027525, Sigma; IB).

Plasmid and lentivirus constructs

TGFpRl, TGFPRl T202D, and TGFpRl K230R were purchased from Addgene and subcloned into the lentivirus pLVX-IRES-Puro vector (Clontech). BamHl -cleaved cDNAs fragments encoding Xenopus dominant negative FGFR1 , constitutively active FGFR1 562E, and its derivative mutants were inserted into the lentivirus pLVX-IRESPuro vector. Plasmids containing multiple mutations were generated using the QuickChange site- directed mutagenesis kit (Stratagene) employing the mouse FRS2 construct as template according to the manufacturer's recommendation. The FRS2 mutants were introduced using the primers in Table 1.

Table 1. Primers for introducing FRS 1 mutants

Primer Primer Sequence (5'-&gt;3')

GCTGAGGAAC AAGTACATAC TTTTGTTAAC SEQ ID NO:l

FRS2 ACTACAGGTG TGCAA

Y196F CTTGCACACC TGTAGTGTTA ACAAAAGTAT SEQ ID NO:2

GTACTTGTTC CTCAGC

GCCCCCTGTC AACAAACTGG TGTTTGAAAA SEQ ID NO:3

FRS2 TATAAACGGG CTATCTATTC

Y306F GAATAGA AG CCCGTT ATA TTTTCAAACA SEQ ID NO:4

CCAGTTTGTT GACAGGGGGC

GAGAAGACCT GCACTATTAA ACTTTGAAAA SEQ I NO:5

FRS2 TTTACCATCT TTGCCTCC

Y349F GGAGGCAAAG ATGGTAAATT TTCAAAGTTT SEQ ID NO:6

AATAGTGCAG GTCTTCTC

GATCCAATGC ATAACTTTGT TAATACAGAG SEQ ID NO:7

FRS2 AATGTAACAG TGCCG

Y392F CGGCACTGTT ACATTCTCTG TATTAACAAA SEQ ID NO:8

GT ATGCATT GGATC SEQ ID NO:9

FRS2 AGGTGGATTT GGAAGG

Y436F CCTTCCAAAT CCACCTGTAT AAAATTGAGT SEQ ID NO:10

TGCCTATGTT CTAAAC

CACGCGGCGC ACAGAGCTGT TCGCTGTGAT SEQ ID NO: 11

FRS2 AGACATTGAG AGAA

Y471 TTCTCTCAAT GTCTATCACA GCGAACAGCT SEQ ID NO: 12

CTGTGCGCCG CGTG

The constructs were verified by sequence analysis (Yale Keck DNA sequencing core facility), and protein expression was confirmed by immunoblot analysis.

Generation of lentiviruses

The production of FRS2 lentivirus was previously described (Murakami JCI in press). For the production of miRNA lentivirus, 10 μg of pMIRNAl carrying the let-7 miRNA expression cassette (System

Biosciences), 5 μg of pMDLg/PRRE, 2.5 μg of RSV-REV, and 3 μg of pMD.2G were co-transfected into 293T cells using Fugene 6. Forty eight hr later, the medium was harvested, cleared by 0.45 μηι filter, mixed with polybrene (Sigma), and applied to the cells. After 6 hr incubation, the virus- containing medium was replaced by fresh medium.

Western Blot Analysis

Tissues and cells were lysed with T-PER (Thermo scientific) containing complete mini protease inhibitors (Roche) and phosphatase inhibitors (Roche). 20 g of total protein from each sample was resolved on a 4%-12% Bis-Tris Gel (Bio-Rad) with MOPs Running Buffer (Bio-Rad) and transferred to nitrocellulose membranes (Bio-Rad). The blots were then probed with various antibodies. Chemiluminescence measurements were performed using SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Fisher Scientific).

RNA isolation, qRT-PCR, and gene expression profiling

RNA was isolated using RNeasy® plus Mini Kit (Qiagen) and converted to cDNA using iScript™ cDNA synthesis kit (Bio-Rad).

Quantitative real-time PCR (qRT-PCR) was performed using Bio-Rad CFX94 (Bio-Rad) by mixing equal amount of cDNAs, iQ™ S YBR® Green Supermix (Bio-Rad) and gene specific primers. All reactions were done in a 25 μΐ reaction volume in duplicate. Data were normalized to endogenous β- actin. Values are expressed as fold change in comparison to control. Primers are listed in Table 2. Mouse TGFp gene expression was quantified via qRT- PCR with TaqMan® Gene Expression Assays (Mm00441726_ml ; Applied Biosystems) and HPRT (Mm00441258_l ; Applied Biosystems) as endogenous control followed the manufacturer's recommendation.

Quantitative PCR analysis of 84 TGF and epithelial to mesenchymal transition (EMT) related genes were performed using Human TGF BMP signaling pathway (PAHS-035D, QIAGEN) and Human Epithelial to Mesenchymal Transition (PAHS-090D, QIAGEN) RT² Profiler™ PCR Arrays following the manufacturer's protocol RT Profiler™ PCR arrays were run on a Bio-Rad CFX96 machine (Bio-Rad). Duplicate arrays were run per condition for control and FRS2 knockdown human umbilical arterial endothelial cells (HUAEC). Data analysis was performed using the manufacturer's integrated web-based software package for the PCR Array System using cycle threshold (Ct)-based fold-change calculations.

Table 2. Primers used for quantitative RT-PCR analysis of mouse and human genes

Gene Primer sequence 5'- 3'

GGCATCTGTAAGTGGTTCAACG SEQ ID NO: 13

Mouse Lin28

CCCTCCTTGAGGCTTCGGA SEQ ID NO: 14

GAT GGGCT C T C T CCAGAT CAG SEQ ID NO: 15

Mouse Myocardin

GGCTGCATCATTCTTGTCACTT SEQ ID NO: 16

GGGCTGTGCTGTCTGTTGA SEQ ID NO: 17

Mouse NG2

TGATTCCCTTCAGGTAAGGCA SEQ ID NO: 18

TCCATGCTAGACTCAGAAGTCA SEQ 3D NO: 19

Mouse PDGFRa

TCCCGGTGGACACAATTTTTC SEQ 1D NO:20

T T C C AG GAGT GAT AC C AG C T T SEQ ID NO:21

Mouse PDGFRp

AGGGGGCGTGATGACTAGG SEQ ID NO:22

GCAGGCAACGATGAAAACTAC SEQ ID NO:23

Mouse Run l

GCAACTTGTGGCGGATTTGTA SEQ ID NO:24

GTCCCAGACATCAGGGAGTAA SEQ ID NO:25

Mouse SM a-actin

T CGGA AC T T C AGCGT CAGG A SEQ ID NO:26

CAACAAGGGTCCATCCT CGG SEQ ID NO:27

Mouse SM22_

ATCTGGGCGGCCTACATCA SEQ ID NO:28

AAAC AG AG C GG AG AT T T G AGC SEQ ID NO:29

Mouse SM-calponin

TGTCGCAGTGTTCCATGCC SEQ ED NO:30

AAGCTGCGGCTAGAGGTCA SEQ ID NO:31

Mouse SM-MHC

CCCTCCCTTTGATGGCTGAG SEQ ID NO:32

TCCCAACTACAGGACCTTTTTCA SEQ ID NO:33

Mouse TGF RI

G CAG T G G AAAC CT GAT C C G SEQ ID NO: 34 CGGCTGCGAGAGAAATTGC SEQ ID NO:35

Mouse Vimentin

CCACTTTCCGTTCAAGGTCAAG SEQ ID NO:36

GTTGTCGACGACGAGCG SEQ K&gt; NO:37

Mouse β-actin

GCACAGAGCCTCGCCTT SEQ ID NO:38

AACAGT GT T GAC AT GAAGAGCC SEQ ID NO:39

Human L-JJJ I

TGTAAAACAGCACGTCATCCTT SEQ ID NO:40

TTCTGTTCGCAGGTGATTGG SEQ ID NO:41

Human Collagen 1A1

CATGTTCAGCTTTGTGGACC SEQ ID NO:42

AACTTGTCACCCTCTTTGCC SEQ ID NO:43

Human FSP1

TCCTCAGCGCTTCTTCTTTC SEQm NO:44

AAAC C AAT T C T T GGAG C AGG SEQ ID NO:45

Human Fibronectin

CCATAAAGGGCAACCAAGAG SEQ ID NO:46

GATCCAACTGCTGCTGAGGT SEQ ID NO:47

Human HMGA2

AGGC GAC C AGGAAAT GGC SEQ ID NO:48

CGGGCATCTGTAAGTGGTTC SEQ ID NO:49

Human Lin28

CAGACCCTTGGCTGACTTCT SEQ H&gt; NO:50

GAGGAGTCAGTGAAGGAGTCA SEQ ID NO: 51

Human N-cadherin

GGCAAGTTGATTGGAGGGATG SEQ ID NO:52

GCCATCACCACTCAAAACTGT SEQ ID NO:53

Human Smad2

GCCTGTTGTATCCCACTGATCTA SEQ ID NO:54

CAAAGCCGGCCTTACAGAG SEQ ID NO:55

Human SM a-actin

AGCCCAGCCAAGCACTG SEQ ED NO:56

GATTTTGGACTGCACTTCGC SEQ ID NO:57

Human SM22a

GTCCGAACCCAGACACAAGT SEQ ID NO:58

CTGGCTGCAGCTTATTGATG SEQ ID NO:59

Human SM-calponin

CTGAGAGAGTGGATCGAGGG SEQ ED NO:60

CAAGCAGAGTACACACAGCAT SEQ 1D N0:61

Human TGFpl

TGCTCCACTTTTAACTTGAGCC SEQ H&gt; NO:62

ACGGCGTTACAGTGTTTCTG SEQ ID NO:63

Human TGF RI

GCACATACAAACGGCCTATCT SEQ ID NO:64

TCTGGTTGTCACAGGTGGAA SEQ ID NO:65

Human TGF RII

GCACGTTCAGAAGTCGGTTA SEQ ID NO:66

CATGAGCCTCTGCATCTTCC SEQ ID NO:67

Human VE-cadherin

ACAGAGCTCCACTCACGCTC SEQ ID NO:68

CGGCTCTTTCGCTTACTGTT SEQ ID NO:69

Human VEGFR2

TCTCTCTGCCTACCTCACCTG SEQ ID NO:70

GCAAAGATTCCACTTTGCGT SEQ BD NO:71

Human Vimentin

GAAATTGCAGGAGGAGATGC SEQ ID NO:72

CAGTCAGCTGCATCTGTAACAC SEQ ID NO:73

Human ZEB1

CCAGGTGTAAGCGCAGAAAG SEQ ID NO:74

CAAGAGGCGCAAACAAGCC SEQ ID NO:75

Human ZEB2

GGTTGGCAATACCGTCATCC SEQ ID NO:76

ATCAAGATCATTGCTCCTCCTGAG SEQ ID NO:77

Human β-actin

CTGCTTGCTGATCCACATCTG SEQ ID NO:78 MicroRNA target prediction

To identify potential miRNA binding sites within the 3'UTR of TGFpRl, the following bioinformatic databases were used: TargetScan, PitTar, and DIANA-microT v3.0.

microRNA real-time PCR analysis

Quantitative PCR analysis of 88 miRNA was performed using Human Cell Differentiation &amp; Development RT² Profiler™ PCR Arrays (MAH-103A, QIAGEN) following the manufacturer's protocol. Validation of microRNA array data was performed with the RT² miRNA qPCR Assays and RT-PCR Primer Sets according to the manufacturer's instructions (QIAGEN). Primers for human mature let-7a (MPH00001A), let-7b

(MPH00002A), let-7c (MPH00003A), let-7d (MPH00004A), Iet-7e

(MPH00005A), let-7f (MPH00006A), let-7g (MPH00007A), mir-98 (MPH00480A), SNORD47 (MPH01660A) were from QIAGEN. Primers for mouse mature let-7a (MPM00483 A), let-7b (MPM00484 A), let-7c

(MP 485A), let-7d (MPM00486A), let-7e (MPM00487A), let-7f

(MPM00488A), let-7g (MPM00489A), let-7i (MPM00490A), mir-98 (MPM00875A) were from QIAGEN. Individual miRNA expression was normalized in relation to expression of small nuclear U6B RNA, a commonly used internal control for miRNA quantification assay. PCR amplification consisted of 10 min of an initial denaturation step at 95 °C, followed by 45 cycles of PCR at 95°C for 30 s, 60°C for 30 s.

Flow cytometry

Cells were incubated with 10 μ^πιΐ Dil-Ac-LDL for 4 hr at 37°C. Cells were then trypsinized, stained with APC-conjugated anti-PEC AM- 1 antibody or isotype control (R&amp;D) and analyzed by FACScan™ (Becton Dickinson) and Flow- Jo Software (TreeStar). Two independent experiments were performed by duplicate.

Transfection of miRNA mimics and luciferase reporter assays For reporter assays, cells were plated in 6-well plates and co- transfected with 1 μg let-7 core 4 firefly luciferase reporter plasmid using Fugene® 6 (Roche). After 24 hr, ceils were transfected with let-7 miRNA mimic (10 nM; QIAGEN) or control oligonucleotides (10 nM; QIAGEN) using HiPerFect® reagent (QIAGEN). After 24 hr of incubation, cells were lysed in passive lysis buffer (Promega) and luciferase activity was measured with the Dual-Luciferase Reporter Assay System (Promega) using TD-20/20 Luminometer (Turner Designs).

Growth factors and chemicals

Recombinant human FGF2 (R&amp;D) and TGF l (Peprotech) were reconstituted in 0.1% BS A/PBS. U0126 (Sigma), a MEK inhibitor, was reconstituted in DMSO and used at a final concentration of 10 uM.

SB431542 (Sigma), a TGFBR1 kinase inhibitor, was reconstituted in DMSO and used at a final concentration of 10 μΜ in cell culture. Actinomycin D (Sigma), a DNA transcription suppressor, was reconstituted in acetone and used at a final concentration of 10 g/ml in cell culture. Cycloheximide (Sigma), a protein synthesis inhibitor, was reconstituted in DMSO and used at a final concentration of 10 μΜ in cell culture.

Generation of mice and embryos

FRS2^fIox/flox (Lin Y, et al. Genesis. 45(9):554 (2007)) and FRS2a 2F (Gotoh N, et al. Proc Natl Acad Sci USA. 101(49):17144 (2004)) mice were previously described. Tie2-Cre transgenic mice or Cdh5-CreERT2 transgenic mice were crossed with R26R-lacZ [B6,129-Gt(ROSA)26Sor^tolSho/J] (JAX SN:003309) or mT/Mg [B6, 129(Cg)-Gt(ROSA)26Sor^{tm4(ACTB dTomat0}'^'^EGFP)Lu7J] (JAX SN:007676) mice to generate endothelial cell-specific reporter mice. For embryo analysis, timed matings were set up and the morning of the vaginal plug was considered as embryonic day 0.5 (E0.5). Embryos were genotyped by PCR analysis of the yolk sacs. PCR genotyping was performed using the primers in Table 3.

Table 3. Primers for PCT genotyping FRS2^tl0X/tu&gt;x mice

Primer Primer Sequence (5'-&gt;3')

AGAATGGTGGCACAAACCAATAATCC SEQ ID NO:79

FRS2 2F

CAATTCTTAACACCCACAAGGCCG SEQ ID NO:80

FRS2¾^¾'¾"ⁱ GAGTGTGCTGT GAT T GGAAGGC AG SEQ ID NO:81

GCACGAGTGTCTGCAGACACATG SEQ ID NO:82

GCGAAGAGTTTGTCCTCAACC SEQ ID NO:83

Rosa26 AAAGTCGCTCTGAGTTGTTAT SEQ ID NO:84

GGAGCGGGAGAAATGGATATG SEQ ID NO:85

GCGGTCTGGCAGTAAAAACTATC SEQ ID NO:86

GTGAAACAGCATTGCTGTCACTT SEQ ID NO:87

Tie2-Cre

CTAGGCCACAGAATTGAAAGATCT SEQ ID NO:88

GT AGGT GGAAATT CT AGC AT C AT CC SEQ ID NO:89

Statistical analysis

Statistical comparisons between groups were performed by the one- way analysis of variance followed by the Student t-test. P values less than 0.05 were considered significant.

Results

To test the role of FGF signaling in EC, RNA interference was used to inhibit the expression of FRS2. Immunofluorescence staining showed that while control HUAEC display a typical rounded/cobblestone morphology, after FRS2 knockdown there was a distinct change in cell shape

accompanied by expression of smooth muscle calponin (SM-calponin), a protein not normally expressed in the endothelium, while an endothelial marker VE-cadherin was still expressed. Western blotting confirmed the appearance of this and other smooth muscle cell markers in FRS2

knockdown cells. FACS analysis showed that both control and FRS2 knockdown EC expressed CD31 and were able to take up Dil-acLDL, ruling out smooth muscle cell contamination. Similar results were obtained in primary mouse FRS2^flox/£lox EC following Ad-Cre transduction (Figs. 9A-9J).

These finding indicated that following FRS2 knockdown EC are undergoing Endo-MT. Since ΤΘΡβ signaling has been implicated in Endo- MT, the expression of genes involved in TGFp signaling was examined. qPCR analysis demonstrated a marked increase in expression of TGFpl and TGFp2, all three TGF receptors and several collagen isoforms that are stimulated by TGFp signaling (Table 4; Figs. 1 A- IF). Western blotting confirmed increased expression and activation of TGFp signaling.

Transduction of HUAEC with dominant negative FGFRl or FRS2 resulted in a similar increase in TGF signaling and smooth

muscle/mesenchymal marker expression (Figs. 10A-10F).

<img file="WO2012167261A2_D0002.tif" />

To confirm the relevance of our findings beyond the primary EC, FRS2 was knocked down in primary human mammary epithelial cells (HuMEC) that are typically used in EMT studies. mRNA expression profiles were assessed using quantitative PCR arrays with cDNA from control or FRS2 knockdown cells. Genes with a statistically significant up-regulation greater than 5 -fold are shown in Table 5. Similar to observations in EC, FRS2 knockdown in HuMEC resulted in the change from the normal rounded epithelial cell to a spindle-like mesenchymal phenotype, increased expression of mesenchymal markers including vimentin, N-cadherin, snail, ZEB1 (zinc finger E-box binding homebox 1) and ZEB2, and decreased expression of EMT repressor miRNAs mir-200b and mir-200c (Figs. 11 A- 11M). FRS2 knockdown in human foreskin and atrial cells also resulted in increased TGFp signaling (Figs. 12A-12H). Collectively, these data support the hypothesis that basal FGF signaling inhibits TGFp-mediated Endo-MT.

<img file="WO2012167261A2_D0003.tif" /> To demonstrate that activation of TGFp signaling following FRS2 knockdown is indeed necessary for Endo-MT, three different experimental approaches were used to silence it. Treatment of FRS2 knockdown EC with TGFpRl inhibitor SB431542 significantly decreased SM-calponin, fibronectin and vimentin expression (Figs. 2A-2C). Similar results were seen after transduction of a dominant negative TGFpRl construct (TGFpRl K230R) (Figs. 2D-2F). Finally, since SMAD2 activation was detected following FRS2 knockdown, its expression was silencing using a specific shRNA. This resulted in a significant decrease in SM-calponin, but not in fibronectin and vimentin expression (Figs. 2G-2I).

Example 2: FGF signaling regulates TGFpRl mRNA stability via regulation of Let7 miRNA expression

Next, the mechanism responsible for increased TGF Rl and SMAD2 expression following FGF signaling shutdown was examined. Quantitative analyses of TGF Rl and Smad2 mRNA half-life showed a marked increase following a knockdown of FRS2 expression (Figs. 3A-3B). This indicates the presence of miRNA regulating the stability of these messages. In silico analysis of TGF Rl and Smad2 messages identified binding sites for let-7 family of miRNAs (SEQ ID NO:91 ) with an exact match to the seed sequence of let-7 in TGFpRl 3'-UTR 75-82 (SEQ ID NO:98) and 3889- 3895 (SEQ ID NO:99) and in Smad2 3'-UTR 3771-3777 (SEQ ID NO: 100) downstream from the stop codon. miRNA array analysis demonstrated a 24 to 120 fold reduction in expression of all let-7 family members following FRS2 knockdown that was confirmed by qPCR (Figs. 3C-3H, Table 6).

<img file="WO2012167261A2_D0004.tif" /> To confirm that FGF signaling controls let-7 miRNA expression, mouse embryos with defective FGF signaling were examined following a knock-in of a mutant FRS2a construct (FRS2a 2F/2F). A gene dosage- dependent reduction in let-7 levels was observed (Figs. 3H-3N).

Example 3: Let-7 regulates TGFpRl expression in endothelial cells

Materials and Methods

In vivo let-7 antagomir delivery

Mice were administrated with either phosphate buffered saline (PBS) or AF 12 complexes at 2 mg/kg body weight in 0.2 ml per injection via lateral tail vein. Measurements of miRNA or mRNA levels in endothelial cells were performed 6 days after the injection.

Results

To further explore let-7 role in regulation of TGFP signaling, the expression of let-7 family members was inhibited in an FGF-independent manner. Transfection of Lin28 (Fig 4A), a known inhibitor of let-7 biogenesis (Viswanathan SR and Daley GQ. Cell. 140(4):445 (2010)) resulted in a profound reduction of let-7b and 7c expression and an increase in TGFpRl and smooth muscle expression (Figs. 4B-4F). Similarly, viral transduction of a let-7 "sponge" (Table 7; Fig. 4E) into EC led to a marked increase in ΤϋΡβΚΙ expression and appearance of Endo-MT markers expression (Figs. 4H-4 ).

<img file="WO2012167261A2_D0005.tif" />

To determine the in vivo relevance of let-7 inhibition in the regulation of TGFpRl, let-7b and let-7c miRNAs were directly targeted in mice using cholesterol formulated antagomirs for improved stability and endothelial cell delivery. A single tail vein injection of 2 mg/kg of cholesterol-formulated let-7b/c antagomirs did not produce any alterations in mice's overall health, body weight or food intake. Six days later the animals were sacrificed and let-7 family expression was determined in freshly isolated primary liver EC. There was a significant reduction in expression of let-7b and let-7c miRNA in EC from antagomirs-treated compared to control mice (Fig. 4L), At the same time, there was no change in expression of other let-7 family members (Fig. 4M). This reduction in let-7b/c levels was confirmed by increased expression of known let-7 target genes HMGA2, CDK6, and CDC25A (Fig 4N). Finally, let-7b/c antagomirs-treated mice EC demonstrated a significant increase in TGFpRI and vimentin expression (Fig. 4N).

While reduction in Let-7b/c expression induced Endo-MT, expression of these miRNAs in primary EC in vitro following FRS2 knockdown (Fig. 5 A) fully inhibited TGF RI and SMAD2 expression and prevented activation of TGF signaling. As a result, expression of all SMC and mesenchymal markers declined to pre-FRS2 knockdown levels (Figs. 5B-5I).

To gain an insight into the molecular mechanism by which FGF controls let-7 expression, it was next determined whether FGF stimulation of normal EC affects its levels. FGF2 treatment of EC resulted in a time dependent increase in expression of all let-7 family miRNAs (Figs. 6A-6G). Since FGFR1 FRS2 complex primarily activates the ERK1/2 pathway (Gotoh N, et al. Proc Natl Acad Sci USA. 101(49):17144 (2004)), the role of ERK1 2 in regulation of let-7 expression was investigated. Treatment of EC with a ME inhibitor U0126 led to a decrease in let-7 expression (Figs. 6H-6M). To determine if ERK activation can restore let-7 expression in EC with suppressed FGF signaling, EC subjected to FRS2 knockdown were transduced with an adenoviral vector encoding a constitutively active ERK (Ad-ME-LA) (Robinson MJ, et al. Curr Biol. 8(21):1141 (1998)) or LacZ control. Transduction of Ad-ME-LA, but not of LacZ, increased let-7 expression, suppressed activation of TGFp signaling including inhibition of Smad2 phosphorylation, and inhibited smooth muscle genes expression (Fig. 6N-6Q), indicating that regulation of ΤΰΡβ signaling by FGF is mediated by activation of the Erkl/2-dependent signaling mechanism.

Example 4: TGFP-mediated Endo-MT plays a role in vascular graft stenosis.

Materials and Methods

Scaffold Fabrication &amp; TEVG Implantation

Scaffolds were constructed from a nonwoven polyglycolic acid (PGA) mesh (Concordia Fibers) and a co-polymer sealant solution of poly-L- lactide and -ε-caprolactone (P(CL/LA)) as previously described (Roh JD, et al. Biomaterials, 29(10):1454 (2008)). For scaffold seeding studies, bone marrow was collected from the femurs of syngeneic C57BL/6 mice.

Following purification of the mononuclear cell component using Histopaque- 1086 (Sigma) centrifugation, one million mononuclear cells were manually pipetted onto the scaffold. The seeded scaffold was incubated in RPMI 1640 Medium (Gibco) overnight prior to implantation as previously described (Roh JD, et al. Biomaterials. 29(10): 1454 (2008)). TEVG scaffolds were inserted into the infrarenal inferior vena cava (IVC) of 8-10 week old, female mice as previously described (Roh JD, et al. Biomaterials. 29(10):1454 (2008)).

In vivo microcomputed tomography

Micro-CT imaging was performed using wild-type CB17 mice at 10 weeks postoperatively as previously described using micro-CT scanner (explore CT120; GE Healthcare, USA).

sFGFRI-IIIc adenovirus administration

sFGFRl-IIIc adenovirus was previously described (Murakami M, et al. J Clin Invest 118(10):3355 (2008)) at a dose of 5xl0¹⁰ viral particles per mouse 1 week prior to TEVG implantation by tail vein injection. Control mice were given equivalent volumes of sterile PBS. Serum level of sFGFRl- IIIc was measured by a Human IgG Subclass Profile kit (Invitrogen).

Mouse treatment with SB431542

Mice treated with TGF RI kinase inhibitor were treated with SB431542 hydrate (Sigma) in DMSO given by intraperitoneal injection twice a day from post-operative day 0 to post-operative day 14 at a dose of 10 mg/kg. Control mice were treated with equivalent volumes of sterile DMSO.

TEVG analysis

Explanted grafts were pressure fixed in 10% formalin overnight and then embedded in paraffin or glycolmethacrylate using previously published methods (Roh JD_S et at Proc Natl Acad Sci USA. 107(10):4669 (2010)). Sections were stained with H&amp;E or Gomori Trichrome. Graft luminal diameters were measured using ImageJ software. Stenosis was defined as greater than 50% decrease in luminal diameter. Critical stenosis was defined as 80% narrowing of the luminal diameter. Graft occlusion was defined as 100% narrowing of the luminal diameter. For EM studies scaffolds were cut into 0.5 mm thick cross-sections and imaged on a FEI XL-30 scanning electron microscope (Hillsboro) as previously described (Roh JD, et al. Biomaterials. 29(10): 1454 (2008)). TGFp positive cell area was measured using ImageJ software. Two separate sections of each explant were counterstained with hematoxalin and imaged at 400X magnification. The number of nuclei was then counted in five regions of each section and averaged. LacZ/SMA colocalized cells were quantified in the same manner using double immunofluorescent staining imaged under 60X confocal magnification.

Tamoxifen administration

100 mg tamoxifen (Sigma) was dissolved in 5 ml corn oil (20 mg/ml final concentration). The solution was mixed at 37°C overnight. Pups were pipette fed with 0.05 mg/g tamoxifen solution every other day for 8 times.

Whole mount X-gal staining

The expression of LacZ in scaffolds was detected by X-gal (β- glactosidase) staining using beta-gal staining kit according to the manufacturer's instructions (MILLIPORE). Following X-gal staining, the scaffolds were refixed, dehydrated, embedded in paraffin, and sectioned at 6 μπι. The paraffin sections were then countered with eosin before being photographed. Results

A tissue-engineered vascular graft (TEVG) stenosis model (Roh JD, et al. Biomaterials. 29(10): 1454 (2008)) was used to examine whether Endo- MT plays a role in vivo. Following implantation into the inferior vena cava in an infrarenal position, TEVG develops extensive neointima composed of SMC and extracellular matrix leading to severe graft stenosis.

Immunocytochemistry and qPCR analysis shows extensive deposition of TGF and increased TGFpi, TGF Rl and vimentin expression (Figs. 7A- 7C).

To determine if transcriptional regulation of TGF Rl by FGF signaling plays a role in TEVG stenosis, a soluble FGF trap (sFGFRl-IIIc), which has been previously demonstrated to virtually shutdown FGF signaling (Murakami M, et al. J ^'Clin Invest. 118(10):3355 (2008)), was systemically expressed one week before implantation of TEVG "seeded" with bone marrow mononuclear cells, a procedure known to dramatically improve the graft patency (Roh JD, et al. Proc Natl Acad Sci USA.

107(10):4669 (2010)). Two weeks after graft implantation, there were significantly higher TEVG neointima burden and stenosis rate in mice injected with Ad-sFGFRl-IIIc compared to saline-injected control mice (Fig. 7D-7E).

To determine if Endo-MT contributes to this process, lineage analysis of neointimal cells was performed following TEVG insertion into Rosa26 mice crossed with Tie2-Cre or Cdh5-CreERT2 mice with the latter Cre activated by tamoxifen administration on day P2. In both cases LacZ-positive cells are found throughout the entire neointima. Confocal analysis of neointima samples double stained for LacZ and SM a-actin demonstrates co- localization of both markers in 40-50% of SMC (Figs. 8A-8B).

Tie2-CreXRosa26 mice were treated with the TGFBR1 inhibitor SB- 431542 at 10 mg kg twice daily by intraperitoneal administration for 2 weeks following implantation of our TEVG (n=16). Matched control mice received intraperitoneal injection of sterile DMSO ^=25). Results of these studies showed that TGFBR1 inhibitor treatment significantly increases TEVG luminal diameter and graft patency at 2 weeks in unseeded grafts (p&lt;0.001 for diameter, p&lt;0.01 for stenosis) (Figure 8C and 8D). Drug treatment also allows for proper neotissue creation with an organized CD31 positive endothelial cell layer lining an SMA positive smooth muscle cell layer in contrast to the typical untreated control graft that occludes as a result of accumulation of SMA positive smooth muscle cells.

In order to unravel the mechanism by which SB-431542 treatment prevents TEVG stenosis, we treated mice from the Tie2 lineage-tracing model (n^lO) with TGFBR1 inhibitor drug and then performed confocal analysis and cellular quantification of TEVG samples double stained for LacZ and SMA. Results of these studies showed that drug treatment improves patency by reducing the occurrence of EMT, as demonstrated by a significant reduction in LacZ-positive smooth muscle cells in occluded grafts in drug treated mice (p&lt;0.05) (Figure 8E).

Example 5: Local delivery of TGFBR1 inhibitor inhibits stenosis without cell seedin and maintains normal neovessel formation

Materials and Methods

Microparticle Synthesis and Characterization

SB-431542 was encapsulated in avidin-coated PLGA microparticles using a modified oil/water single emulsion technique as previously described (Fahmy, T.M., et al. Biomaterials 26:5727-5736 (2005)). Control microparticles were synthesized without SB-431542. Microparticle size and morphology were analyzed via scanning electron microscopy (SEM) as previously described (Roh, J.D., et al. Proc Natl Acad Sci USA 107:4669- 4674 (2010)).

Preparation of Adhesive Peptide Tether

Poly-L-lysine-LC-LC-biotin (pLLB) was synthesized and used as an adhesive peptide tether to enhance loading of PGA-P(CL/LA) scaffolds with avidin-coated microparticles. 1.66 mg EZ-Link sulfo NHS-LC-LC-biotin was reacted with 10 ml of a 0.1 mg/ml solution of poly-L-lysine (MW 70,000-150,000, Sigma) in PBS for 2 hours at 4C, dialyzed in PBS for 72 hours, and stored at 4C. Loading ofTEVG Scaffolds with SB-431542-eluting Microparticles Nonspecific adsorption of avidin-coated PLGA microparticles to PGA-P(CL/L A) scaffolds not treated with pLLB was titrated by incubating trimmed scaffolds with 1 ml of 1, 5, or 10 mg/ml of microparticles in PBS for 10, 30 or 60 minutes. Particle-loaded TEVG scaffolds were immediately snap frozen in liquid nitrogen and lyophilized for 6 hours before imaging. Scaffold loading efficiency was determined with ImageJ software from three SEM images per scaffold cross-section, inner surface, and outer surface by calculating the mean surface density of particles. The effect of scaffold pretreatment with pLLB on scaffold loading efficiency was assessed from particle loading density as above after PGA-P(CL/LA) scaffolds were incubated with 1 ml of 0.01, 0.1 or 1 mg/ml pLLB for 60 minutes on a rotary shaker, washed with dH20, incubated with 1 ml 5 mg/ml avidin-coated PLGA microparticles, washed with d¾0, snap frozen in liquid nitrogen, lyophilized for 6 hours, and imaged by SEM. For in vitro and in vivo studies, PGA-P(CL/LA) scaffolds were incubated with pLLB for 30 minutes at 20C, washed with dH20, incubated with 5 mg ml empty or SB-431542-eluting avidin-coated PLGA microparticles for 30 minutes, washed with dH20, snap frozen in liquid nitrogen, and lyophilized for 6 hours before desiccated storage.

Characterization ofSB-431542 Release from Microparticles and Scaffolds

Total encapsulation was approximated as the amount of SB-431542 released over a 14-day period. Percent encapsulation efficiency was calculated as total encapsulation divided by maximum theoretical encapsulation. 5 mg of avidin-coated PLGA microparticles containing SB- 431542, PGA-P(CL/LA) trimmed scaffolds and treated with pLLB and SB- 431542-eluting microparticles as above, and SB-431542~eIuting PGA- P(CL/LA) trimmed scaffolds were incubated with PBS in triplicate on a rotary shaker at 37°C. Samples were removed at specific time points and centrifuged at 13200 RPM for 10 minutes. 300 μΐ of supernatant was drawn and replaced with 300 μΐ PBS. Concentration of SB-431542 in supernatant diluted with 600 μΐ PBS was determined by spectrophotometry at 320 nm.

Bioactivity of Encapsulated SB-431542

SB-431542 was released into 1 ml PBS from 10 mg avidin-coated PLGA microparticles and one untrimmed SB -431542-eluting PGA- P(CL/LA) scaffold in 2 ml microcentrifuge tubes at 37°C. At 48 hours, samples were centrifuged at 13200 RPM for 10 minutes, supernatants were collected and analyzed by spectrophotometry at 320 nm. SB-431542 concentrations were adjusted to 10 μΜ by dilution with PBS. 3T3 human fibroblasts were plated at 500,000/well and stimulated at confluence with 700 ul 10 μΜ SB-431542 in PBS eluted from particles or scaffolds, a stock solution of 10 or 1 μΜ SB-431542 containing &lt;1% DMSO, or PBS. After 30 minutes at 37°C, cells were washed and stimulated with 200 ul 2 ng/ml recombinant human TGF-βΙ (BD Biosciences) for 1 hour at 37C. Cells were lysed and protein samples were separated by gel electrophoresis with a 12% polyacrylamide gel and probed with primary antibody to phosphorylated SMAD-2 (ser426/ser428, Cell Signaling Technology) and secondary goat anti-rabbit IgG (Cell Signaling Technology). The gel was stripped and reprobed with anti-SMAD2/3 as a loading control.

Results

A microparticle system was developed for local delivery of the TGFBRl inhibitor SB-431542 in order to minimize possible effects of systemic delivery. This system was characterized to show that there is steady release of the drug across the full 2-week time course during which the grafts are implanted (Figures 14A and 14B), and showed that the released drug maintains its biologic activity. A simpler local drug delivery system was also developed by which the TGFBRl inhibitor was added to the solvent used to make the grafts. This system also demonstrated a favorable release profile and continued biologic activity of the released drug (Figures 14A and 14B). Both types of drag-eluting grafts were then implanted in the mouse model (n=10 for drug in microparticles, n=24 for drug in solvent) and their patency compared to grafts with empty microparticles (n=10) or control grafts (n=25). Results of these studies showed that local drug delivery significantly increases patency at 2 weeks in unseeded grafts (p&lt;0.01) and also enabled neotissue creation (Figures 14C and 14D).